Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CombiCoR-Vax
- Development stage
- Unknown
- Lead developer
- IRST IRCCS
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
CombiCoR-Vax is an investigational sequential immunochemotherapy regimen developed by the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" for the treatment of refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). The treatment strategy involves an induction phase with the PD-1 checkpoint inhibitor pembrolizumab and an autologous dendritic cell vaccine loaded with tumor-associated antigens. This is followed by a maintenance phase consisting of the chemotherapy combination trifluridine/tipiracil and the anti-VEGF monoclonal antibody bevacizumab. The regimen aims to overcome the inherent immunoresistance of MSS colorectal tumors by priming the immune system with cellular immunotherapy before transitioning to standard-of-care cytotoxic and anti-angiogenic therapies. This approach is currently being evaluated in a Phase 2 multicenter trial.
- Other names
- CombiCoR-Vax regimen
02
Targets
pMHC (Peptide-MHC complex family)PDCD1 (Programmed cell death protein 1 receptor)TYMP (Thymidine phosphorylase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on CombiCoR-Vax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CombiCoR-Vax.